



Sen. Terri Bryant

**Filed: 5/7/2026**

10400HB4203sam001

LRB104 15932 BAB 37517 a

1 AMENDMENT TO HOUSE BILL 4203

2 AMENDMENT NO. \_\_\_\_\_. Amend House Bill 4203 by replacing  
3 everything after the enacting clause with the following:

4 "Section 5. The Illinois Insurance Code is amended by  
5 changing Section 356u as follows:

6 (215 ILCS 5/356u)

7 Sec. 356u. Pap tests and prostate cancer screenings.

8 (a) A group policy of accident and health insurance that  
9 provides coverage for hospital or medical treatment or  
10 services for illness on an expense-incurred basis and is  
11 amended, delivered, issued, or renewed on or after January 1,  
12 2028 ~~2024~~ shall provide coverage, without imposing a  
13 deductible, coinsurance, copayment, or any other cost-sharing  
14 requirement, for all of the following:

15 (1) An annual cervical smear or Pap smear test for all  
16 insureds.

1           (2) An annual prostate cancer screening for insureds  
2           upon the recommendation of a physician licensed to  
3           practice medicine in all its branches for:

4                     (A) asymptomatic individuals age 50 and over;

5                     (B) African-American individuals age 40 and over;

6           and

7                     (C) individuals age 40 and over with a family  
8           history of or genetic predisposition to prostate  
9           cancer.

10           (3) An annual screening ~~Surveillance tests~~ for ovarian  
11           cancer for insureds who are at risk for ovarian cancer  
12           using (i) CA-125 serum tumor marker testing, (ii)  
13           transvaginal ultrasound, and (iii) pelvic examination.

14           (a-5) A group policy of accident and health insurance that  
15           provides coverage for hospital or medical treatment or  
16           services for illness on an expense-incurred basis and is  
17           amended, delivered, issued, or renewed on or after January 1,  
18           2028 shall, in addition to the coverage required under  
19           paragraph (3) of subsection (a), provide coverage for all  
20           medically viable methods for the detection and diagnosis of  
21           ovarian cancer for insureds who are at risk for ovarian  
22           cancer, including, but not limited to, ultrasounds, magnetic  
23           resonance imagings (MRIs), x-rays, computed tomography (CT)  
24           scans, and CA-125 blood test screenings. The coverage required  
25           under this subsection may be subject to a deductible,  
26           coinsurance, or other cost sharing.

1 (b) This Section shall not apply to agreements, contracts,  
2 or policies that provide coverage for a specified disease or  
3 other limited benefit coverage.

4 (c) This Section does not apply to coverage of prostate  
5 cancer screenings to the extent such coverage would disqualify  
6 a high-deductible health plan from eligibility for a health  
7 savings account pursuant to Section 223 of the Internal  
8 Revenue Code.

9 (d) For the purposes of this Section:

10 "At risk for ovarian cancer" means:

11 (1) having a family history (i) with one or more  
12 first-degree relatives with ovarian cancer, (ii) of  
13 clusters of relatives with breast cancer, or (iii) of  
14 nonpolyposis colorectal cancer; ~~or~~

15 (2) testing positive for BRCA1 or BRCA2 mutations; ~~or~~

16 (3) having a high level of CA-125, as indicated by a  
17 blood test screening.

18 "Prostate cancer screening" means medically viable methods  
19 for the detection and diagnosis of prostate cancer, including  
20 a digital rectal exam and the prostate-specific antigen test  
21 and associated laboratory work. "Prostate cancer screening"  
22 includes medically necessary subsequent follow-up testing as  
23 directed by a health care provider, including, but not limited  
24 to:

25 (1) urinary analysis;

26 (2) serum biomarkers; and

1           (3) medical imaging, including, but not limited to,  
2           magnetic resonance imaging.

3           ~~"Surveillance tests for ovarian cancer" means annual~~  
4           ~~screening using (i) CA-125 serum tumor marker testing, (ii)~~  
5           ~~transvaginal ultrasound, (iii) pelvic examination.~~

6           (Source: P.A. 102-1073, eff. 1-1-23; 103-30, eff. 1-1-25.)

7           Section 99. Effective date. This Act takes effect January  
8           1, 2028."